Abstract
The clinical significance of carbon-ion radiotherapy (CIRT) for adenocarcinoma (AC) of the uterine cervix has been assessed in several single-institutional studies. To validate the significance, we conducted a multi-institutional survey of CIRT for locally advanced AC (LAAC) of the uterine cervix. We retrospectively analyzed the clinical outcomes of patients with stage IIB-IVA LAAC of the uterine cervix who underwent chemo-CIRT or CIRT alone between April 2010 and April 2016. Patients received 74.4 Gy (relative biological effectiveness [RBE]) in 20 fractions of CIRT or 55.2 Gy (RBE) in 16 fractions of CIRT plus three sessions of brachytherapy. Patients aged ≤ 70 years with adequate bone marrow and organ function were administered cisplatin weekly (40 mg/m2 per week for up to 5 weeks). Fifty-five patients were enrolled in this study. The median follow-up period was 67.5 months. The 5-year overall survival (OS) and local control (LC) rates were 68.6% and 65.2%, respectively. Multivariate analysis showed that the initial tumor response within 6 months was significantly associated with LC and OS. The present study represents promising outcomes of CIRT or chemo-CIRT for LAAC of the uterine cervix, especially in the cases showing initial rapid regression of the tumor.
Highlights
Uterine cervical cancer is the fourth most common type of cancer among women worldwide
We have investigated the clinical significance of carbon-ion radiotherapy (CIRT) for locally advanced AC (LAAC) of the uterine cervix for decades [22,23,24,25]
A recent phase I/II study assessing the feasibility of concurrent cisplatin administration with CIRT for LAAC showed that 2-year local control (LC) and overall survival (OS) rates were 71% and 88%, respectively [23]
Summary
Uterine cervical cancer is the fourth most common type of cancer among women worldwide. In 2018, the global incidence of uterine cervical cancer was estimated to be 569,000, with 311,000 women dying from the disease [1]. Out of the different histological types of uterine cervical cancer, squamous cell carcinomas account for approximately 80% of all cervical cancers, and adenocarcinoma (AC) accounts for approximately 20% [2]. AC of the uterine cervix is known to be less radiosensitive than cervical squamous cell carcinoma. Previous studies with radiation therapy (RT)/CCRT treatment showed lower local control (LC) rates for AC of the uterine cervix than cervical squamous cell carcinoma. Since the use of imageguided brachytherapy (IGBT) has been accepted as a treatment for cervical cancer [14], several studies have reported improved LC rates [15,16]. New therapeutic strategies are required for AC of the uterine cervix
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
